TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05989555

Intervention type: OTHER
Intervention: Blood drawing
Description: Blood is drawn twice in all subjects. Once before treatment with radioacitve iodine and once after.

Intervention type: OTHER
Intervention: Blood drawing
Description: Blood is drawn twice in all subjects. Once before treatment with radioacitve iodine and once after.
Study: NCT04817306

Intervention type: DEVICE
Intervention: Multi-cancer early detection test
Description: Blood collection and multi-cancer early detection testing

Intervention type: DEVICE
Intervention: Multi-cancer early detection test
Description: Blood collection and multi-cancer early detection testing

Intervention type: DEVICE
Intervention: Multi-cancer early detection test
Description: Blood collection and multi-cancer early detection testing
Study: NCT05401994

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: screw retained arch bar
Description: maxillomandibular fixation with bone screwed arch bar

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional Erich's Arch Bar
Description: maxillomandibular fixation with conventional arch bar fixed to the teeth
Study: NCT05554107

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training program
Description: A 16-week training program consisting of 2-3 visits per week, and 60 minutes per visit. The program will be done as group exercise under supervision from physiotherapists and/or physicians with special interest in POTS.
Study: NCT06412354

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EasyCross™ first-in human
Description: At T0 the patient will undergo the TAVR procedure including the investigational procedure with the VIVHEART EasyCross™ catheter.~The interventional cardiologist will introduce the VIVHEART EasyCross™ catheter through the femoral artery with a percutaneous access according to the clinical practice through a vascular introducer on an already positioned guidewire. An operator in the procedure room will start a chronometer at this point to measure the investigational device crossing procedure duration.~The VIVHEART EasyCross™ catheter will be progressed into the aorta and up to the aortic valve.~At that time the external part of the VIVHEART EasyCross™ catheter will be opened to allow the self-centering of the catheter on the aortic valve. The guidewire will be introduced and once having crossed the valve the VIVHEART EasyCross™ catheter will be retracted by the physician and removed from the patient's body.
Study: NCT04777201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab
Description: Faricimab 6 mg will be administered by intravitreal (IVT) injection into the study eye according to the personalized treatment interval (PTI) dosing regimen for the duration of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab
Description: Faricimab 6 mg will be administered by intravitreal (IVT) injection into the study eye according to the personalized treatment interval (PTI) dosing regimen for the duration of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. The sham procedure will be administered to participants as appropriate during the first 12 weeks of this study in order to maintain the masking of the initial faricimab PTI.
Study: NCT05695586

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Self-Compassion (MSC) training
Description: 8-week Mindful Self-Compassion (MSC) intervention protocol, developed by Germer and Neff (2013, 2019). After the training, participants will enter a 12-month phase of regular MSC-based supervised practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction (MBSR) training
Description: 8-week Mindfulness Based Stress Reduction (MBSR) intervention protocol, as developed by Stahl \& Goldstein (2010). After the training, participants will enter a 12-month phase of regular MBSR-based supervised practice.
Study: NCT06254612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-624
Description: Once daily oral administration of two capsules totaling 20 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily oral administration of two matching placebo capsules
Study: NCT05867277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music
Description: The students in the intervention group listened to music for 15 min before and during the peripheral intravenous catheter placement skill practice.
Study: NCT05963347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golidocitinib
Description: Daily dose. Starting dose of golidocitinib is 75 mg QD. If tolerated, subsequent cohorts will test ascending doses of golidocitinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP Regimen
Description: CHOP will be administered in a 21-day cycle for a maximum of 6 cycles.
Study: NCT05121558

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Participants will have instructional yoga classes twice each week over the course of 8 weeks. Each yoga class will be 60 minutes, and it will be taught by an experienced yoga instructor. Participants will be provided with a home-based guided program for days classes are not held. Participants in the yoga group will also have the option to participate in a recorded final check-in session after they have completed their 16 yoga classes. The discussion facilitator will follow the Semi-Structured Interview Guide to further understand participants' experiences in the yoga group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education control
Description: Participants will have educational sessions over 8 weeks. The sessions will be on the causes and impact of Chemotherapy-Induced Peripheral Neuropathy (CIPN), how yoga may help with CIPN, and how different therapies may help with CIPN. To encourage participation and adherence, patients in the EC group will receive sixteen free yoga sessions after completing the study. Patients in the EC group will be asked to not go for their own yoga classes locally until their participation in the study is completed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants in the usual care control group will complete the same assessments as the other two arms. To encourage participation and adherence, patients in the UC group will receive sixteen free yoga sessions after completing the study. Patients in the UC group will be asked to not go for their own yoga classes locally until their participation in the study is completed.
Study: NCT05937893

Intervention type: OTHER
Group type: OTHER
Intervention: Keto-ester followed by Magnetic Resonance Spectroscopic Imaging (MRSI) scans
Description: Following baseline scans, the participant will orally consume the keto-ester, for subsequent scans which will include repeated BHB MRSI acquisitions to dynamically measure BHB labeling in the brain, followed by a final GABA MRSI acquisition.

Intervention type: OTHER
Group type: OTHER
Intervention: Keto-ester followed by Magnetic Resonance Spectroscopic Imaging (MRSI) scans
Description: Following baseline scans, the participant will orally consume the keto-ester, for subsequent scans which will include repeated BHB MRSI acquisitions to dynamically measure BHB labeling in the brain, followed by a final GABA MRSI acquisition.
Study: NCT05779449

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotics and Probiotics supplementation
Description: From the 1st day to the 15th day (included) patients with MS in the Pre-Pro group will receive daily:~1 capsule of Probactiol Duo, Metagenics (6 billions of Saccharomyces boulardii and 8,5 billions of probiotics including Bifidobacterium lactis Bi-07®, Bifidobacterium lactis Bl-04, Lacticaseibacillus paracasei Lpc-37, Lactobacillus acidophilus NCFM®)~1. packet of Probactiol Stips, Metagenics (4 g inulin enriched with oligofructose)~   From the16th day to the 365th day (included) patients with MS in the Pre-Pro group will receive daily:~2. capsules of Probactiol HMO Combi, Metagenics (7,5 billions of Lactobacillus acidophilus NCFM®, 7,5 billions of Bifidobacterium lactis Bi-07®, 2,5 ug Vitamine D3, 320 ug Vitamine A, 100 mg Threonine, 250 mg 2'-Fucosyllactose).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplementation
Description: 1-year supplementation with two placebo capsules/day containing starch, the probiotic bacteria carrier.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: peripheral blood withdrawal
Description: 40 ml of blood for the isolation of Peripheral Blood Cells (PBMCs) and T cells.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood withdrawal
Description: 40 ml of blood for the isolation of Peripheral Blood Cells (PBMCs) and T cells.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Intermittent theta burst stimulation (iTBS) protocol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Intermittent theta burst stimulation (iTBS) protocol
Study: NCT05984771

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Epineuron
Description: Superoxide Dismutase (SOD, 70 UI), Palmitoylethanolamide (PEA, 300 mg) Alpha Lipoic Acid (ALA, 300 mg), vitamins B6 (1.5 mg), B1 (1.1 mg), B12 (2.5 mcg), E (7.5 mg), Nicotinamide (9 mg) and minerals (Mg 30 mg, Zn 2,5 mg) in one tablet (Epineuron)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Usual care
Study: NCT04963088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A317
Description: Subjects will be treated with BGB A317 200 mg IV on Day 1 during each 21-day cycle. BGB A317 will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: oral administration daily d1-d14, q3w;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 30 mg/m² IV on Day 1 during each 21-day cycle. during each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m² orally twice daily (bid) Days 1 through 14 (14 days total) during each 21-day cycle. Capecitabine will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.
Study: NCT05333523

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy guided selective elective neck irradiation
Description: Patients will undergo sentinel lymph node biopsy. Based on the histopathologic status of the sentinel lymph node(s), selective elective neck irradiation is performed with standard radiation treatment of the primary tumor.~There are 3 possible treatment scenarios.~1. Bilateral elective neck irradiation is indicated when sentinel lymph nodes at both sides of the neck contain metastases or when sentinel lymph node detection fails.~2. Unilateral elective neck irradiation is indicated when sentinel lymph node(s) at one side of the neck contain metastases.~3. Full omission of elective neck irradiation is indicated when all sentinel lymph nodes are free of metastases.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard elective neck irradiation
Description: Patients randomized to the control arm will receive the standard of care, according to (inter)national clinical practice guidelines. This will consist of (chemo)radiotherapy to the primary tumor with standard elective neck irradiation in all patients. No sentinel lymph node biopsy will be performed.
Study: NCT04741438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab and IPILIMUMAB
Description: The combination of Nivolumab+Ipilimumab will be given to patients as follows:~* Nivolumab: 3 mg/kg IV over 30 minutes every 2 weeks for 4 cycles.~* Ipilimumab 1 mg/kg IV over 60 minutes every 6 weeks for 4 cycles. After completion of 4 courses with ipilimumab, patients continue receiving nivolumab IV at the dose of 480 mg Q4W in the absence of disease progression or unacceptable toxicity for a maximum of 18 months.~Nota Bene: A cycle is defined as a 6-weeks period.~The planned treatment period is 24 months~Nivolumab and Ipilimumab must be injected the same day every 6 weeks (Q6W). In case of toxicity, dose will be delayed, but will not be reduced.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pazopanib Oral Tablet [Votrient]
Description: Treatment by pazopanib 800 mg/day per os, continuously during a maximum 24 months.~In case of toxicity, dose will be delayed and reduced.
Study: NCT06087770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM3321
Description: Intravenous infusion, once a week, 28 days for a dosing cycle
Study: NCT05918536

Intervention type: DIAGNOSTIC_TEST
Intervention: evaluate the quality of surgical margins achievable with the use of navigated Intraoperative CT
Description: Noninterventional, prospective study of patients operated on for musculoskeletal neoplasms designed to evaluate the quality of surgical margins achievable with the use of navigated Intraoperative CT
Study: NCT06529341

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-definition transcranial direct current stimulation
Description: HD-tDCS stimulated AD left OFC (2 mA, 20 minutes, cathode electrode placed in the Fp 1 area, and the remaining four positive electrodes placed AF3, AF7, Afz, Fpz, forming a circular 41 focused electric field mode for stimulation, twice a day, 20 minutes interval for 5 days)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-definition transcranial direct current stimulation pseudo-stimulation control group
Description: The treatment parameters of the electrode were the same as the test group, the stimulation current rose to the same 2 mA current in the test group within 30 seconds, and the pre-stimulation for 1 minute, then gradually to 0 mA.
Study: NCT04619017

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Segmental allergen challenge
Description: All subjects will undergo bronchoscopy with administration of standardized allergen extract to one segment of the lung.
Study: NCT06100536

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music-with-movement
Description: The intervention group participants will receive 12 weekly music-with-movement interventions facilitated by trained staff in a community centre or a residential care home. The duration lasts 30 minutes to one hour. It can be carried out individually or with up to six persons in a group. The intervention will be supported by the standalone music-with-movement system.
Study: NCT05459415

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reducing Excision Margins
Description: Reducing Excision Margins After Neoadjuvant Chemoimmunotherapy
Study: NCT05892237

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bronchial artery interventional therapy
Description: After successful anesthesia, right femoral artery puncture was performed by Seldinger method. 5F-Yashrio catheter is chosen to locate the bronchial artery of the diseased side at the level of the thoracic aortotracheal bifurcation. Angiography was performed (Osu 300mg/ml, 3ml/s, total 8ml, 200Psi) to visualize tumor blood supply artery before infusion of chemo+PD-1 inhibitor and embolism.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy drug
Description: Nano-paclitaxel 260 mg/m2, d1, ivgtt, q3w+Cisplatin 75mg/m2, d1, ivgtt,q3w.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: 60Gy/2Gy/30f

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: PD-1 inhibitor (Tirelizumab) 200mg, d1, ivgtt, 30-60min, q3w.
Study: NCT05563337

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arteriography and renal denervation
Description: Diagnostic renal Arteriography - Randomization - Renal denervation
Study: NCT04949243

Intervention type: BEHAVIORAL
Intervention: Behavioral questionaires
Description: Behavioral surveys and questionaires
Study: NCT06575790

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simple Meal Bolusing
Description: Participants will enter pre-determined numbers for small, medium, or large carbohydrate meals rather than using precise carbohydrate counting
Study: NCT05563337

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Arteriography without renal denervation
Description: Diagnostic renal Arteriography - Randomization
Study: NCT05696964

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing training enhanced with artificial intelligence
Description: The training in motivational interviewing that medical residents will receive will make use of an artificial intelligence measurement tool, Real-time Assessment of Dialogue in Motivational Interviewing (ReadMI), that produces a spectrum of relevant MI metrics.
Study: NCT06575790

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate counting
Description: Participants will be instructed to enter accurate carbohydrate counts to the best of their ability for all meals and snacks
Study: NCT05157659

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]F-AraG PET-scan
Description: \[18F\]F-AraG PET scans are performed to assess the accumulation of activated T-cells in the tumour and healthy tissue.
Study: NCT05385198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VOICE care
Description: I phase:build a relationship with parents and where the Values of the parents and NICU staff is shared.~II phase: discuss with the parents the Opportunities the parents can have to be more involved in the care of their baby.~III phase: Integration of the involvement of the parents in the care of their baby. The experiences of parents need to be shared with the NICU staff. Any raising issue about the involvement of care by the parents can be discussed and see if improvement is needed.~IV phase:Control of the knowledge about the care of their baby before going home and if the parents have any issues which need to be arranged before discharge.~V phase:Evaluation. During this conversation the overall experiences of the parents will be discussed and if there are any further questions related to the care of their baby at home will be explored and discussed.
Study: NCT06552117

Intervention type: OTHER
Group type: OTHER
Intervention: an elastoMRI sequence
Description: Addition of an MRI elasto sequence performed during MRI performed as part of the treatment

Intervention type: OTHER
Group type: OTHER
Intervention: an elastoMRI sequence
Description: Addition of an MRI elasto sequence performed during MRI performed as part of the treatment

Intervention type: OTHER
Group type: OTHER
Intervention: an elastoMRI sequence
Description: Addition of an MRI elasto sequence performed during MRI performed as part of the treatment
Study: NCT06405568

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Description: Participants will receive a copy of physical activity (PA) recommendations plus a PA motivation package - namely three 20-minute online webinars (explaining PA benefits and how to get started), digitized PA materials (integrating evidence-based behaviour change tools, and a digitized logbook (to track PA).
Study: NCT06569394

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Broad Spectrum Cannabidiol (bsCBD) 400 mg
Description: Participants in this Arm will take 400 mg of bsCBD daily. Participants will take medication by mouth with food in the morning and evening.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in this Arm will take a medically inert placebo. Participants will take medication by mouth with food in the morning and evening.
Study: NCT04870255

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Left Dorsolateral Prefrontal Cortex (L-DLPFC)
Description: Participants who are randomly assigned to this group will receive active iTBS (intermittent theta burst stimulation) to the left DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Magventure Magpro X100 TMS system.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dorsomedial Prefrontal Cortex (DMPFC)
Description: Participants who are randomly assigned to this group will receive active iTBS (intermittent theta burst stimulation) to the DMPFC. Stimulation intensity will be standardized at 100% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Magventure Magpro X100 TMS system.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Participants who are randomly assigned to this group will receive sham stimulation to the left DLPFC.~Sham stimulation will be delivered using the Magventure Magpro X100 TMS system.
Study: NCT05910944

Intervention type: PROCEDURE
Intervention: Shunt surgery
Description: Shunt surgery according to each local centers routine

Intervention type: PROCEDURE
Intervention: Shunt surgery
Description: Shunt surgery according to each local centers routine
Study: NCT05859451

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tobacco Heating System (THS)
Description: Participant who are not willing to quit cigarette smoking during the study duration will switch from cigarettes to using THS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking abstinence
Description: Participant who are willing to quit cigarette smoking and will not use any electronic nicotine delivery system during the study duration
Study: NCT04927884

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803
Description: Dose: 15 μg/kg subcutaneously (SC)~Frequency: administered on Day 8 of each cycle (every 3 weeks)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-L1 t-haNK
Description: Dose: \~2 × 10\^9 cells intravenously (IV)~Frequency: administered on Days 1 and 8 of each cycle (every 3 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-Hziy
Description: Phase 1b:~Dose level 1: Sacituzumab govitecan-hziy (7.5 mg/kg IV) Dose level 2: Sacituzumab govitecan-hziy (10 mg/kg IV) Dose level -1 (if needed): Sacituzumab govitecan-hziy (5.0 mg/kg IV)~Phase 2: Dose based on Phase 1b Recommended Phase 2 Dose (IV)~Frequency: administered on Days 1 and 8 of each cycle (every 3 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Dose: 25 mg capsules taken twice per day by mouth (PO)~Frequency: to be taken Days 1-15 and 15-19 of each cycle (every 3 weeks)
Study: NCT05668741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-522 mRNA therapy
Description: Oral inhalation using nebulizer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-522 mRNA therapy
Description: Oral inhalation using nebulizer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-522 mRNA therapy
Description: Oral inhalation using nebulizer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Tablet for oral administration.